Seres Therapeutics (MCRB) Common Equity (2014 - 2026)

Seres Therapeutics has disclosed Common Equity across 13 years of filings, most recently posting $34.5 million for Q2 2026.

• In Q2 2026, Common Equity rose 4.81% year-over-year to $34.5 million; the TTM figure through Jun 2026 stood at $34.5 million (up 4.81% YoY), while the FY2025 annual figure was $44.2 million, up 220.79% from the prior year.
• Common Equity came in at $34.5 million for Q2 2026 at Seres Therapeutics, up from $26.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $81.0 million in Q1 2022 to a low of -$87.1 million in Q2 2024.
• Average Common Equity over 5 years is $12.2 million, with a median of $23.5 million recorded in 2022.
• Year-over-year, Common Equity slumped 515.99% in 2023 and surged 258.16% in 2024.
• Over 5 years, Common Equity stood at $10.8 million in 2022, then tumbled by 515.99% to -$44.9 million in 2023, then soared by 130.73% to $13.8 million in 2024, then surged by 220.79% to $44.2 million in 2025, then decreased by 21.9% to $34.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $34.5 million in Q2 2026, $26.5 million in Q1 2026, and $44.2 million in Q4 2025.